Yuankai Shi

机构：Chinese Academy of Medical Sciences & Peking Union Medical College

发表论文 8 篇 · 总被引 60 次 · h-index 4

代表论文

• Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial (2024 · The Lancet Respiratory Medicine · 被引 21)
• Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC (2022 · Journal of Translational Medicine · 被引 18)
• Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial (2025 · The Lancet Respiratory Medicine · 被引 13)
• Identification of novel serological autoantibodies in Chinese prostate cancer patients using high-throughput protein arrays (2022 · Cancer Immunology Immunotherapy · 被引 8)
• Efficacy and safety of furmonertinib plus anlotinib as first-line treatment for locally advanced or metastatic NSCLC patients: a single-arm, phase I/II trial (2025 · SSRN Electronic Journal)
• Efficacy and safety of anlotinib combined with sintilizumab in locally advanced or metastatic anaplastic thyroid carcinoma. (2024 · Journal of Clinical Oncology)